Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company’s results and corporate developments.

What:   Stereotaxis second quarter 2022 financial results conference call
   
When: Tuesday, August 9, 2022 at 10:00 a.m. ET (7:00 a.m. PT)
   
Dial In Number: To access the live call, dial 888-394-8218 (US and Canada) or 1-856-344-9221 (International) and give the participant pass code 9211068.
   
Webcast: To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/
   
Call Replay: A phone replay of the call will be available for one month beginning approximately two hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Media Contact:
Bethanne Schluter
Director, Marketing & Communications
   
Kimberly Peery
Chief Financial Officer
 
   
314-678-6100
Investors@Stereotaxis.com
 
   

Staff

Recent Posts

Optimi Health Obtains U.S. FDA Drug Establishment Registration

The Company is now recognized by the U.S. FDA to support the cross-border supply of…

57 minutes ago

Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025

Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease…

8 hours ago

Best Supplements For Muscle Growth: Top Legal Bodybuilding Supplements & Anabolic Steroids For Bulking, Cutting & Strength

Backed by Wolfson Brands (UK) Limited, Discover the best supplements for muscle growth, including top…

24 hours ago

Mitolyn Reviews 2025: Exploring Faux Reviews, Consumer Complaints, & How to Buy Real Mitolyn Purple Peel Exploit!

Mitolyn Mitolyn Seattle, May 03, 2025 (GLOBE NEWSWIRE) -- As more individuals become health-conscious, and…

24 hours ago

Buy Ibutamoren MK 677 SARMS for Sale Online: MK-677 Before After Results – Where to Order Legal Ibutamoren SARM OTC, Buyers Guide from CrazyBulk

CrazyBulk CrazyBulk New York City, May 03, 2025 (GLOBE NEWSWIRE) -- If you’re serious about…

24 hours ago

Bioma Review 2025: Revolutionizing Gut Health or Just Another Fad? Honest Analysis Inside By Bioma Probiotic!

Gut transformation through Bioma a perfectly blended combination of probiotics prebiotics and postbiotics Bioma Bioma…

24 hours ago